FR14C0033I1 - - Google Patents

Info

Publication number
FR14C0033I1
FR14C0033I1 FR14C0033C FR14C0033I1 FR 14C0033 I1 FR14C0033 I1 FR 14C0033I1 FR 14C0033 C FR14C0033 C FR 14C0033C FR 14C0033 I1 FR14C0033 I1 FR 14C0033I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0033I1 publication Critical patent/FR14C0033I1/fr
Application granted granted Critical
Publication of FR14C0033I2 publication Critical patent/FR14C0033I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR14C0033C 2001-10-04 2014-04-16 Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine Active FR14C0033I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
FR14C0033I1 true FR14C0033I1 (en:Method) 2014-06-13
FR14C0033I2 FR14C0033I2 (fr) 2014-11-14

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0033C Active FR14C0033I2 (fr) 2001-10-04 2014-04-16 Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine

Country Status (38)

Country Link
US (10) US7144884B2 (en:Method)
EP (2) EP1749818B1 (en:Method)
JP (3) JP3896116B2 (en:Method)
KR (3) KR100783346B1 (en:Method)
CN (1) CN1319958C (en:Method)
AR (2) AR036659A1 (en:Method)
AT (2) ATE441631T1 (en:Method)
AU (2) AU2002333220C1 (en:Method)
BE (1) BE2014C036I2 (en:Method)
BR (3) BR122012009534C8 (en:Method)
CA (1) CA2462110C (en:Method)
CO (1) CO5580746A2 (en:Method)
CY (3) CY1107924T1 (en:Method)
DE (2) DE60225162T3 (en:Method)
DK (2) DK1749818T3 (en:Method)
EA (2) EA011096B1 (en:Method)
EG (1) EG25095A (en:Method)
ES (2) ES2328725T3 (en:Method)
FR (1) FR14C0033I2 (en:Method)
HR (1) HRP20040220A2 (en:Method)
HU (3) HU230189B1 (en:Method)
IL (1) IL160655A0 (en:Method)
IS (2) IS2578B (en:Method)
LT (1) LTC1436271I2 (en:Method)
LU (1) LU92397I2 (en:Method)
ME (1) ME00039B (en:Method)
MX (1) MXPA04002959A (en:Method)
MY (1) MY140950A (en:Method)
NL (1) NL300652I2 (en:Method)
NO (3) NO326443B1 (en:Method)
NZ (1) NZ531556A (en:Method)
PL (2) PL209253B1 (en:Method)
PT (2) PT1436271E (en:Method)
RS (2) RS52865B (en:Method)
SI (1) SI1436271T1 (en:Method)
UA (2) UA81749C2 (en:Method)
WO (1) WO2003029232A1 (en:Method)
ZA (1) ZA200401583B (en:Method)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
DE602004013314T2 (de) * 2003-04-04 2008-08-07 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer
KR101107536B1 (ko) * 2003-04-04 2012-01-31 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 저해제로서의4-(2-페닐술파닐-페닐)-피페리딘 유도체
CN1767829A (zh) * 2003-04-04 2006-05-03 H.隆德贝克有限公司 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物
HRP20080478T3 (hr) * 2003-04-04 2009-02-28 H. Lundbeck A/S Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
DE602004014190D1 (de) 2003-12-23 2008-07-10 Lundbeck As Valby H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
WO2006084870A2 (en) * 2005-02-10 2006-08-17 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
UA95801C2 (ru) * 2006-06-16 2011-09-12 Х. Луннбек А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
PT2044043E (pt) * 2006-06-16 2012-03-26 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina como um composto que combina a reabsorção de serotonina, à actividade de 5-ht3 e 5-ht1a para o tratamento de perturbação congnitiva
AR061480A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H 4-[2-(4-metilfenilsulfanil)-fenil]piperidina como inhibidor combinado de la recaptacion de serotonina y norepinefrina.
JP5318757B2 (ja) * 2006-06-16 2013-10-16 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
BRPI0921596B1 (pt) 2008-11-14 2021-10-26 Theravance Biopharma R&D Ip, Llc Compostos de 4-[2-(2-fluorfenoximetil)fenil]piperidina, composição, método de preparação e uso relacionados
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
CA2759456C (en) * 2009-04-24 2017-10-31 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
ES2427628T3 (es) * 2009-08-24 2013-10-31 H. Lundbeck A/S Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina
CA2779108C (en) * 2009-10-30 2018-01-02 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
JP5705239B2 (ja) 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
EA030433B1 (ru) 2010-04-30 2018-08-31 Такеда Фармасьютикал Компани Лимитед Энтеросолюбильная таблетка
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
EP3135656B1 (en) 2011-06-20 2019-02-27 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MX354547B (es) 2011-11-14 2018-03-09 Alfasigma Spa Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión.
MX344144B (es) 2012-01-03 2016-12-07 H Lundbeck As Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)feni l] piperazina.
US9499504B2 (en) 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
RU2635528C2 (ru) 2012-12-13 2017-11-13 Х. Лундбекк А/С Композиции, содержащие вортиоксетин и донепезил
EP2958903B1 (en) * 2013-02-22 2017-04-12 H. Lundbeck A/S Vortioxetine manufacturing process
ES2724246T3 (es) * 2013-04-04 2019-09-09 Lek Pharmaceuticals Nuevo proceso para la síntesis de 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
EP2894154A1 (en) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
JP7000321B2 (ja) * 2015-07-17 2022-02-10 アンスティテュ・パストゥール 衛星細胞の自己再生および／または分化の促進剤としての使用のための５－ヒドロキシトリプタミン１ｂ受容体刺激剤
WO2017029377A1 (en) * 2015-08-19 2017-02-23 Amneal Pharmaceuticals Company Gmbh Process for preparation of vortioxetine hydrobromide
EP3362058B1 (en) * 2015-10-14 2021-09-01 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
EP3478289A1 (en) 2016-07-01 2019-05-08 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
KR20190038840A (ko) 2016-07-15 2019-04-09 앵스띠뛰 파스퇴르 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제
US20210284615A1 (en) * 2016-07-22 2021-09-16 Qingeng Li Vortioxetine analogue and use and preparation thereof
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
EP3582759A4 (en) 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
WO2018154451A1 (en) * 2017-02-23 2018-08-30 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
KR102551433B1 (ko) 2017-04-25 2023-07-04 하. 룬드벡 아크티에셀스카브 보르티옥세틴 hbr 알파-형태의 제조 방법
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
WO2019242889A1 (en) 2018-06-20 2019-12-26 Vio Ag Pharmaceuticals S.A. A one-pot organo-pseudocatalytic c-h activation approach for the preparation of vortioxetine and vortioxetine intermediate
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2022052391A1 (zh) 2020-09-10 2022-03-17 苏州富德兆丰生化科技有限公司 伏硫西汀的合成方法
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151751B1 (en:Method) 1971-04-13 1973-11-19
CS151755B1 (en:Method) 1971-04-13 1973-11-19
CS151752B1 (en:Method) 1971-04-13 1973-11-19
CS151753B1 (en:Method) 1971-04-13 1973-11-19
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
JP3897360B2 (ja) * 1995-01-23 2007-03-22 第一アスビオファーマ株式会社 虚血性疾患に基づく症状の改善又は治療薬及びそれに有用な化合物
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2230209T3 (es) * 1997-10-31 2005-05-01 Daiichi Suntory Pharma Co., Ltd. Procedimiento para preparar n-((4-fenil)metilfenil)piperazinas.
HUP0201904A3 (en) 1999-04-02 2003-04-28 Icos Corp Bothell Inhibitors of lfa-1 binding to icams and uses thereof
WO2001010842A2 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
AU2152101A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
WO2001049681A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
WO2002059108A1 (en) * 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2003053942A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
HRP20080478T3 (hr) * 2003-04-04 2009-02-28 H. Lundbeck A/S Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
PT2044043E (pt) * 2006-06-16 2012-03-26 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina como um composto que combina a reabsorção de serotonina, à actividade de 5-ht3 e 5-ht1a para o tratamento de perturbação congnitiva

Also Published As

Publication number Publication date
BR0212733A (pt) 2004-11-16
EP1749818A3 (en) 2008-04-02
ES2298425T3 (es) 2008-05-16
BR122012023120B1 (pt) 2017-03-21
BRPI0212733B8 (pt) 2021-05-25
EP1749818A2 (en) 2007-02-07
EP1749818B1 (en) 2009-09-02
ATE386730T1 (de) 2008-03-15
PL209253B1 (pl) 2011-08-31
ES2328725T3 (es) 2009-11-17
AU2002333220B2 (en) 2008-02-07
BE2014C036I2 (en:Method) 2021-11-22
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
AR036659A1 (es) 2004-09-22
CA2462110C (en) 2010-05-11
AU2006215994B2 (en) 2008-11-13
US8476279B2 (en) 2013-07-02
CN1561336A (zh) 2005-01-05
CN1319958C (zh) 2007-06-06
JP2005505585A (ja) 2005-02-24
HU228956B1 (en) 2013-07-29
UA81749C2 (uk) 2008-02-11
NO2014011I2 (no) 2015-08-31
US9708280B2 (en) 2017-07-18
HRP20040220A2 (en) 2005-02-28
HK1072600A1 (en) 2005-09-02
JP2007031447A (ja) 2007-02-08
AU2006215994A9 (en) 2006-10-05
PT1436271E (pt) 2008-04-10
JP2007051149A (ja) 2007-03-01
IL160655A0 (en) 2004-07-25
US20050014740A1 (en) 2005-01-20
FR14C0033I2 (fr) 2014-11-14
US7138407B2 (en) 2006-11-21
LTC1436271I2 (lt) 2016-09-12
AU2006215994A2 (en) 2006-10-05
BR122012023120B8 (pt) 2022-01-18
HUS1400012I1 (hu) 2020-12-28
US20140163043A1 (en) 2014-06-12
CY1110064T1 (el) 2015-01-14
HUP0402313A3 (en) 2010-03-29
ZA200401583B (en) 2005-05-25
JP3955614B2 (ja) 2007-08-08
JP3955613B2 (ja) 2007-08-08
US20180127389A1 (en) 2018-05-10
MXPA04002959A (es) 2004-07-05
CY1107924T1 (el) 2013-09-04
EP1436271A1 (en) 2004-07-14
HUP0402313A2 (hu) 2005-02-28
DE60233608D1 (de) 2009-10-15
UA93857C2 (uk) 2011-03-25
KR100842702B1 (ko) 2008-07-01
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
US20060084662A1 (en) 2006-04-20
AU2006215994A1 (en) 2006-10-05
ATE441631T1 (de) 2009-09-15
IS2578B (is) 2010-02-15
AR066460A2 (es) 2009-08-19
US20070060574A1 (en) 2007-03-15
EP1436271B1 (en) 2008-02-20
PL210551B1 (pl) 2012-02-29
NO2014011I1 (no) 2014-05-13
CO5580746A2 (es) 2005-11-30
BR122012009534B8 (pt) 2019-01-29
KR100770194B1 (ko) 2007-10-25
WO2003029232A1 (en) 2003-04-10
BR0212733B1 (pt) 2014-05-13
RS27704A (en) 2006-10-27
KR20060118020A (ko) 2006-11-17
CA2462110A1 (en) 2003-04-10
KR100783346B1 (ko) 2007-12-07
CA2462110E (en) 2003-04-10
EA007537B1 (ru) 2006-10-27
CY2014022I1 (el) 2015-12-09
DK1749818T3 (da) 2009-10-12
NO20083446L (no) 2004-04-21
PL368442A1 (pl) 2005-03-21
EA200400498A1 (ru) 2004-08-26
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
US9090575B2 (en) 2015-07-28
ME00039B (me) 2010-06-10
KR20070103515A (ko) 2007-10-23
US20120302553A1 (en) 2012-11-29
RS52865B (en) 2013-12-31
US20160137620A1 (en) 2016-05-19
KR20040047886A (ko) 2004-06-05
IS8806A (is) 2009-03-10
NO20041628L (no) 2004-04-21
US20110009423A1 (en) 2011-01-13
EA011096B1 (ru) 2008-12-30
SI1436271T1 (sl) 2008-06-30
DE60225162T2 (de) 2009-02-12
NL300652I1 (en:Method) 2016-01-18
EA200601269A1 (ru) 2007-02-27
EP1436271B3 (en) 2022-04-20
RS20120158A2 (en) 2012-10-31
EG25095A (en) 2011-08-17
IS7164A (is) 2004-02-26
US7148238B2 (en) 2006-12-12
US20060089368A1 (en) 2006-04-27
PT1749818E (pt) 2009-10-06
JP3896116B2 (ja) 2007-03-22
AU2002333220C1 (en) 2023-10-05
MY140950A (en) 2010-02-12
DK1436271T6 (da) 2022-06-27
DK1436271T3 (da) 2008-06-09
HU230189B1 (hu) 2015-09-28
NO326443B1 (no) 2008-12-08
NL300652I2 (en:Method) 2016-01-18
RS20120158A3 (en) 2013-10-31
ES2298425T7 (es) 2022-06-27
US10844029B2 (en) 2020-11-24
AU2002333220A2 (en) 2003-04-14
US20210276966A1 (en) 2021-09-09
EA007537B3 (ru) 2015-02-27
MEP6508A (xx) 2010-02-10
NO332355B1 (no) 2012-09-03
US7144884B2 (en) 2006-12-05
IS2732B (is) 2011-04-15
CY2014022I2 (el) 2015-12-09
BR122012009534B1 (pt) 2018-02-27
US7683053B2 (en) 2010-03-23
DE60225162D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
BE2022C531I2 (en:Method)
BE2022C502I2 (en:Method)
BE2017C059I2 (en:Method)
BE2017C057I2 (en:Method)
BE2017C051I2 (en:Method)
BE2017C032I2 (en:Method)
BE2016C051I2 (en:Method)
BE2015C046I2 (en:Method)
BE2017C050I2 (en:Method)
BE2014C052I2 (en:Method)
BE2014C036I2 (en:Method)
BE2014C026I2 (en:Method)
BE2011C034I2 (en:Method)
BE2007C047I2 (en:Method)
AU2002307149A8 (en:Method)
BE2014C006I2 (en:Method)
BRPI0209186B1 (en:Method)
BRPI0204884B1 (en:Method)
CH1379220H1 (en:Method)
BE2014C008I2 (en:Method)
BE2016C021I2 (en:Method)
BRPI0101486B8 (en:Method)
BE2012C051I2 (en:Method)
JP2002243428A5 (en:Method)
JP2002235437A5 (en:Method)